Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.31 |
| ▸ | NPBWR1 | P48145 | 3/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21632114 | 0.89 | NPBWR1 (0.31) | FNTAFNTBPGGT1BADAMTS5NPBWR1 | |
| SCHEMBL20031125 | 0.87 | NPBWR1 (0.30) | FNTAFNTBPGGT1BNPBWR1MCHR1 | |
| SCHEMBL20031127 | 0.86 | FNTA (0.33) | FNTAFNTBPGGT1BADAMTS5NPBWR1 | |
| SCHEMBL20031604 | 0.80 | CYP3A4 (0.36) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL21632243 | 0.77 | CYP3A4 (0.39) | FNTAFNTBPGGT1BHTR2ASLC6A4 | |
| SCHEMBL21632262 | 0.75 | CYP3A4 (0.38) | FNTAFNTBPGGT1BHTR2ASLC6A4 | |
| SCHEMBL20031603 | 0.74 | CYP3A4 (0.37) | FNTAFNTBPGGT1BNPBWR1HTR2A | |
| SCHEMBL20031435 | 0.73 | AR (0.38) | FNTAFNTBPGGT1BHTR2ASLC6A4 | |
| SCHEMBL21632373 | 0.67 | CYP17A1 (0.31) | FNTAFNTBPGGT1B | |
| SCHEMBL21631894 | 0.66 | CYP3A4 (0.44) | HTR2ASLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200029563-A1 | NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYLDIOXOLANE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2020-01-30 | — | — | US | disclosed |
| US-20200029563-A1 | NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYLDIOXOLANE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2020-01-30 | — | — | US | disclosed |
| WO-2018060088-A1 | 5-SUBSTITUTED IMIDAZOLYLMETHYLDIOXOLANE DERIVATIVES AS FUNGICIIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200029563-A1 | NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYLDIOXOLANE DERIVATIVES | PIP5K1B, PIP5K1A, PIP5K1C | FNTA 1944/4885FNTB 2008/4885PGGT1B 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.